C-Type Natriuretic Peptide (1-53) (human)

C-Type Natriuretic Peptide (1-53) (human) is a synthetic research peptide in the natriuretic peptide family. The listed sequence/design is Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys(Disulfide bridge: Cys37-Cys54). Natriuretic peptides share a characteristic disulfide-constrained ring that is central to receptor activation. Defined analogs are commonly studied in cyclic-GMP and receptor-binding assays.

• receptor or binding assays
• competition experiments
• enzymatic-processing studies
• antibody or antigen controls
• analytical method development
• LC-MS/HPLC reference work
• comparative structure-activity experiments

Because this product may be a fragment, substituted analog, stereochemical variant, or terminally modified form, its activity should not be assumed to be identical to the native parent peptide. Peptide solubility, aggregation, adsorption to surfaces, and stability can vary with sequence, concentration, pH, ionic strength, and terminal modifications, so assay-specific reconstitution and storage conditions should be validated experimentally.

1. Structural requirements of C-type natriuretic peptide for cGMP accumulation (PMID 1314580).